ASCAT 2023 | Diverse participation in SCD blood group genotyping for improved transfusion outcome
Sara Trompeter, MD, University College London Hospitals NHS Foundation Trust, London, UK, emphasizes the need for inclusion of a diversity of sickle cell disease (SCD) patients in the Sickle Cell and Thalassemia Blood Group Genotyping Program, to improve transfusion outcomes for a wide range of patients. She mentions the push from Genomics England and the National Institute for Health Care Research (NIHR) BioResource to address the underrepresentation of minority groups, specifically individuals of African ethnicity. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
